Calgary, Alberta–(Newsfile Corp. – September 1, 2022) – NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp. or “EnerSpar”) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, announced today that it agrees to offer 170,195 common shares of the Company at a deemed

Calgary, Alberta–(Newsfile Corp. – August 25, 2022) – NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp.) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients suffering from traumatic spinal cord injuries, released a business update and reported financial results for the quarter ended June 30, 2022. 

https://www.newsfilecorp.com/release/133194/James-Richardson-the-Former-CEO-of-EnerSpar-Updates-Shareholders-After-the-Completion-of-RTO-with-NurExone-Biologic

Newsfile Corp. July 19, 2022·5 min read Calgary, Alberta–(Newsfile Corp. – July 19, 2022) – NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp.) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal injuries and other Central Nervous System (“CNS”) indications, announced the signing of a Material

https://finance.yahoo.com/news/nurexone-provides-corporate-120000076.html

“ExoTherapy”, NurExone’s proprietary Exosome siRNA loaded product, is being developed to recover functionality in patients with traumatic spinal cord injuries read more

Bnei-Brak, Israel–(Newsfile Corp. – June 22, 2022) – NurExone Biologic Inc. (formerly, EnerSpar Corp.) (TSXV: NRX) (“NurExone” or the “Company“) is pleased to announce that, further to its press release of June 15, 2022 announcing the closing of its reverse takeover transaction, it will commence trading on the TSX Venture Exchange (the “TSXV“) under

Calgary, Alberta–(Newsfile Corp. – June 15, 2022) – NurExone Biologic Inc. (formerly, EnerSpar Corp.) (TSXV: NRX) (the “Company“) is pleased to announce that it has completed its previously announced business combination transaction (the “Transaction“) with NurExone Biologic Ltd. (“NurExone“). read more

Calgary, Alberta–(Newsfile Corp. – May 17, 2022) – EnerSpar Corp. (TSXV: ENER) (FSE: 5E0) (“EnerSpar” or the “Company“) and NurExone Biologic Ltd. (“NurExone“) are pleased to announce that the TSX Venture Exchange (“TSXV” or the “Exchange“) has conditionally accepted the previously announced reverse takeover transaction (the “RTO“) of EnerSpar pursuant to a

Calgary, Alberta–(Newsfile Corp. – March 15, 2022) – EnerSpar Corp. (TSXV: ENER) (FSE: 5E0) (“EnerSpar” or the “Company“) is pleased to announce it has entered into an arrangement agreement (the “Arrangement Agreement“) dated March 10, 2022, between the Company and 1222150 B.C. Ltd (the “Subsidiary“), a wholly-owned subsidiary of the Company, with